News

Sanofi plans to axe 2000 jobs
Enlarge image

BusinessFrance

Sanofi plans to axe 2000 jobs

06.07.2012 - The French pharma giant is preparing for a major overhaul of activities in its home market.

Exact numbers are not yet final, but French unions already fear the worst. An estimate of 2,000 jobs lost is “probably close to reality,” said Thierry Bodin, a representative of the CGT union after a meeting with managers today. Europe’s third-biggest drugmaker wants to regroup its research in the Paris region and around Lyon, he said. This might be the end for research in Toulouse, where the blockbuster Plavix blood thinner was developed, and Montpellier. The company also plans to eliminate support functions and cut jobs at its Pasteur vaccine division, Bodin said.

Reuters reports, that Chief Executive Chris Viehbacher told employees that the unspecified number of job cuts, at its Toulouse and Montpellier sites, would be achieved through voluntary redundancies, early retirement and internal mobility. Manufacturing sites in France would not be affected by the project. Jean-Marc Podvin, a spokesman for Sanofi, said in a telephone interview with Bloomberg Businessweek, that no job cut figures were given and all options remain open for Toulouse. Montpellier could become a centre focused on clinical development, he added.

The company’s CEO Viehbacher began to restructure Sanofi in 2009 reducing headcount, closing plants and dropping the least promising projects. As part of a strategic shift, the French drugmaker is aiming at reducing internal research and having other actors, such as small biotechs, academic research to find new molecules and vaccines.

In its course to concentrate on its core competencies, Sanofi has decided to divest its 19.3% stake in the Yves Rocher Group, which operates in a variety of sectors, including cosmetics, home care products and clothing. The Rocher family which already controls most of the company will buy the shares and raise its stake to more than 95%.

http://www.european-biotechnology-news.com/news/news/2012-03/sanofi-plans-to-axe-2000-jobs.html

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

FinancingUK

29.10.2014 British VC fundraiser Advent Life Sciences has raised €184m with its second fund. The money will help seed and build life sciences companies in the UK, Europe and the US, the company said.

BusinessSwitzerlandGermanyUK

28.10.2014 Swiss pharma company Novartis is selling its influenza vaccines business to Australian biopharma specialist CSL Ltd for US$275m.

PoliticsSwitzerland

23.10.2014 Just one day before its planned initial listing, Swiss Molecular Partners has cancelled its IPO. The reason: "unfavourable market conditions".

PoliticsEU

23.10.2014 Jean-Claude Juncker can breathe a sigh of relief as MEPs voted “yes” by a large majority to his team of European Union Commissioners. Previous to the vote, Juncker had shifted the EMA back to the health commissioner in response to protests.

FinancingFrance

21.10.2014 Yet another European company is looking for money on the US stock exchange – French DBV Technologies SA is all set up for its secondary listing on NASDAQ. The French biotech company hopes to rake in US$98m for its peanut allergy patches.

FinancingDenmark

18.10.2014 After raising US$220.5m (€172m) with its IPO, fast Forward Pharma’s lucky streak hits an obstacle on the road to success with shares falling 17% on its first day of trading.

M&AUKItaly

17.10.2014 Abandoned at the altar: Abbvie has dropped plans to acquire UK’s Shire following new US tax rules. This puts a stop to one of the biggest pharma mergers planned this year.

FinancingUKBelgium

15.10.2014 Bicycle Therapeutics wins €25m backing by major pharma venture capitalists for the development of a new class of oncology drugs.

FinancingGermanySwitzerlandNetherlands

13.10.2014 Biotechnology IPOs are back in fashion – German Probiodrug AG wants to raise €32m with its IPO, whilst Swiss Molecular Partners AG hopes the launch of its IPO will gain a revenue of €145m.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THERAMETRICS0.08 CHF14.29%
  • CYTOS0.17 CHF13.33%
  • MORPHOSYS75.99 EUR4.89%

FLOP

  • EPIGENOMICS4.15 EUR-4.38%
  • EVONIK26.20 EUR-2.42%
  • PAION2.80 EUR-2.10%

TOP

  • BIOFRONTERA2.82 EUR15.6%
  • BB BIOTECH166.45 EUR11.2%
  • HBM91.50 CHF8.6%

FLOP

  • MAGFORCE5.55 EUR-19.0%
  • PAION2.80 EUR-14.6%
  • CO.DON2.65 EUR-13.1%

TOP

  • SANTHERA89.00 CHF2182.1%
  • CO.DON2.65 EUR150.0%
  • WILEX2.25 EUR81.5%

FLOP

  • CYTOS0.17 CHF-95.7%
  • MERCK KGAA71.68 EUR-41.5%
  • 4SC0.98 EUR-41.0%

No liability assumed, Date: 31.10.2014